businesspress24.com - Theravance to Report Second Quarter 2015 Financial Results on July 29, 2015
 

Theravance to Report Second Quarter 2015 Financial Results on July 29, 2015

ID: 1373984

(firmenpresse) - SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 07/22/15 -- Theravance, Inc. (NASDAQ: THRX) announced today that it will report financial results for the second quarter ended June 30, 2015 after market close on Wednesday, July 29, 2015. Theravance management will host a webcast and conference call at 5:00 p.m. EDT that day to discuss the financial results and provide a corporate update.

To participate in the live call by telephone, please dial (877) 837-3908 from the U.S., or (973) 890-8166 for international callers. A live webcast of the call will be available online from the investor relations section of the company website at and will be archived there for 30 days. A telephone replay of the call will be available by dialing (855) 859-2056 from the U.S., or (404) 537-3406 for international callers and entering the confirmation code 84038673.



Theravance, Inc. is focused on bringing compelling new medicines to patients in areas of unmet need by leveraging its significant expertise in the development, commercialization and financial management of bio-pharmaceuticals. Theravance''s portfolio is anchored by the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®, which were jointly developed by Theravance and GSK. Under the agreement with GSK, Theravance is eligible to receive associated royalty revenues from RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA® and, if approved and commercialized, VI monotherapy, as well. In addition, Theravance retains a 15% economic interest in future payments made by GSK to Theravance BioPharma for earlier-stage programs. For more information, please visit Theravance''s website at .

ANORO®, RELVAR®, BREO® and ELLIPTA® are trademarks of the GlaxoSmithKline group of companies.

(THRX-F)



Eric d''Esparbes
Senior Vice President and Chief Financial Officer
650-238-9640




Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:



Leseranfragen:



PresseKontakt / Agentur:



drucken  als PDF  an Freund senden  Alimera Sciences Signs Knight Therapeutics as Exclusive ILUVIEN(R) Distributor for Canada
Insys Therapeutics to Report Second Quarter 2015 Results
Bereitgestellt von Benutzer: Marketwired
Datum: 22.07.2015 - 14:05 Uhr
Sprache: Deutsch
News-ID 1373984
Anzahl Zeichen: 0

contact information:
Contact person:
Town:

SOUTH SAN FRANCISCO, CA


Phone:

Kategorie:

Drugs


Anmerkungen:


Diese Pressemitteilung wurde bisher 151 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Theravance to Report Second Quarter 2015 Financial Results on July 29, 2015
"
steht unter der journalistisch-redaktionellen Verantwortung von

Theravance, Inc. (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Theravance, Inc.



 

Who is online

All members: 10 562
Register today: 1
Register yesterday: 2
Members online: 0
Guests online: 68


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.